Related Experiment Videos
Update on liver transplantation using cyclosporine
1Department of Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Hannover, Germany.
Transplantation Proceedings
|December 29, 2004
Summary
Cyclosporine significantly improved liver transplant survival. Modern monitoring and new drugs enhance outcomes, but long-term complications and individualized immunosuppression remain key challenges.
Area of Science:
- Immunology
- Transplantation Medicine
- Pharmacology
Background:
- Cyclosporine introduction in 1983 dramatically increased 1-year liver transplant survival.
- Improved cyclosporine formulations (Neoral) offer more stable pharmacokinetics.
- C(2) monitoring enhances cyclosporine exposure estimation, improving therapeutic control.
Purpose of the Study:
- To review advancements in immunosuppression for liver transplantation.
- To discuss the impact of evolving immunosuppressive strategies on patient outcomes.
- To highlight challenges in long-term management and individualized therapy.
Main Methods:
- Review of historical data and clinical advancements in immunosuppression.
- Analysis of pharmacokinetic monitoring and drug formulations.
- Discussion of emerging immunosuppressive agents and their safety profiles.
Main Results:
- Cyclosporine has more than doubled 1-year survival rates in liver transplantation.
- Newer agents like mycophenolate mofetil and monoclonal antibodies offer alternative rejection prevention.
- Focus is shifting to managing long-term complications and optimizing individualized immunosuppression.
Conclusions:
- Optimized cyclosporine therapy and novel immunosuppressants have improved liver transplant success.
- Preventing long-term complications (infections, metabolic disorders, PTLD) is crucial.
- Individualized immunosuppression strategies tailored to patient factors are essential for future success.